dhr. dr. G.C.M. Linssen

Aandachtsgebieden

CV

Nevenfuncties

Samenwerkingsverbanden

BIG-nummer

Wetenschappelijke publicaties en onderzoeken

• Heart failure treatment in patients with and without obesity with an ejection fraction below 50

  Aga YS, Radhoe SP, Aydin D, Linssen GCM, Rademaker RC, Geerlings PR, Gent MWF van , Aksoy I, Oosterom L, [et al.] .
  Eur J Clin Invest. 2023; 53 (7):e13976.
  

• The effects of positive psychology interventions on well-being and distress in patients with cardiovascular diseases: A systematic review and Meta-analysis

  Tönis KJM, Kraiss JT, Linssen GCM.
  J Psychosom Res. 2023; 170:111328.
  

• Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial

  Brugts JJ, Radhoe SP, Clephas PRD, Aydin D, Gent MWF van, Szymanski MK, Rienstra M, Heuvel MH van den , Fonseca CA da, Linssen GCM.
  The Lancet 2023; 401(10394):2113-2123.
  

• Phenotypic patient profiling for improved implementation of guideline-directed medical therapy: An exploratory analysis in a large real-world chronic heart failure cohort.

  Radhoe SP, Clephas PRD, Linssen GCM, Oortman RM, Smeele FJ, Drimmelen AA van, Schaafsma HJ, Westendorp PH, Brunner- La Rocca HP, Brugts JJ.
  Front Pharmacol. 2023; :Doi: 10.3389/fphar.2023.1081579. eCollection 2023..
  

• Non-cardiovascular medication and readmission for heart failure: an observational cohort study

  Kruik-Kollöffel WJ, Vallejo-Yagüe E, Movig KLL, Linssen GCM, Heintjes EM, Palen J van der.
  Int J Clin Pharm. 2022; 44(3):762-768.
  

• Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

  Cikes M, , Planinc I, Claggett B, Cunningham J, Milicic D, Sweitzer N, Senni M, , Gori M, Linssen GCM.
  JACC Heart Fail. 2022; 10(5):336-346.
  

• Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries:The CAPACITY-COVID Collaborative Consortium and LEOSS Study Group

  Linschoten M, Uijl A, Schut A, Jakob CEM, Romao LR, LEOSS Study Group , Linssen GCM, Veneman ThF, Zaal R.
  European Heart Journal 2021; :doi:10.1093/eurheartj/ehab656.
  

• Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases

  Kruik-Kollöffel WJ, Palen J van der , Doggen CJM, Maaren MC van , Kruik HJ, Heintjes EM, Movig KLL, Linssen GCM.
  PLoS One. 2020; 15(12):e0244231.
  

• Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study

  Birkeland KL, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, Banerjee A, Thuresson M, Okami S, Garal-Pantaler E.
  Diabetes Obes Metab. 2020; 22(9):1607-1618.
  

• Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: an analysis of the CHECK-HF registry

  Linssen GCM, Veenis JF, Brunner-La Rocca HP, Pol PEJ van , Engelen DJM, Tooren RM van , .
  Neth Heart J. 2020; 28(6):334-344.
  

• Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

  Solomon SD, Vaduganathan M, Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer M, Desai A, Linssen GCM.
  Circulation 2020; 141(5):352-361.
  

• Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial

  Buiten RA, Ploumen EH, Zocca P, Heijden LC van der , Kok MM, Danse PW, Schotborgh CE, Scholte M, Man FH da, Linssen GCM.
  JAMA Cardiol. 2019; :doi: 10.1001/jamacardio.2019.1776. [Epub ahead of print].
  Publicatie openen

• Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015

  Kruik-Kollöffel WJ, Linssen GCM, , Kruik HJ, Movig KL, Heintjes EM, Palen J van der .
  Heart Fail Rev. 2019; :doi: 10.1007/s10741-019-09777-2. [Epub ahead of print].
  Publicatie openen

• Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.

  Brunner-La Rocca HP, Linssen GCM, Smeele FJ, Drimmelen AA van , Schaafsma HJ, Westendorp PH, Rademaker PC, Kamp HJ van de , Hoes AW, Brugts JJ.
  JACC Heart Fail 2019; Jan;7(1):13-21.
  Publicatie openen

• Effectiveness of the European Society of Cardiology/Heart Failure Association website 'heartfailurematters.org' and an e-health adjusted care pathway in patients with stable heart failure: results of the 'e-Vita HF' randomized controlled trial

  Wagenaar KP, Broekhuizen BD, Jaarsma T, Kok I, Mosterd A, Willems FF, Linssen GCM, Agema WR, Anneveldt S, Lucas CM.
  Eur J Heart Fail. 2018; :doi: 10.1002/ejhf.1354. [Epub ahead of print].
  Publicatie openen

• Thin composite wire strut, durable polymer-coated versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug eluting stents in allcomers with coronary artery disease

  Birgelen C von, Zocca P, Buiten RA, Jessurun GA, Schotborgh CE, Roguin A, Danse PW, Benit E, Aminian A, Houwelingen KG van, Anthonio RL, Stoel MG, Somi S, Hartmann M, Linssen GCM.
  Lancet. 2018; 392 (10154):1235-1245.
  Publicatie openen

• High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial

  Zocca P, Kok MM, Heijden LC van der , Danse PW, Schotborgh CE, Scholte M, Hartmann M, Linssen GCM, Doggen CJ, Birgelen C von.
  Cardiovasc Drugs Ther. 2018; :doi: 10.1007/s10557-018-6823-9. [Epub ahead of print].
  Publicatie openen

• A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure.

  Linssen GCM, Jaarsma T, Hillege HL, Voors AA, Veldhuizen DJ van .
  Neth Heart J. 2018; :doi: 10.1007/s12471-018-1145-x. [Epub ahead of print].
  Publicatie openen

• High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.

  Zocca P, Kok MM, Heijden LC van der , Houwelingen KG van , Hartmann M, Man FH de , Louwerenburg JH, Knottnerus IL, Linssen GCM.
  Int J Cardiol. 2018; :doi: 10.1016/j.ijcard.2018.03.116. [Epub ahead of print].
  Publicatie openen

• Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.

  Heijden LC van der , Kok MM, Zocca P, Jessurun GA, Schotborgh CE, Roguin A, Benit E, Danse PW, Linssen GCM.
  Am Heart J. 2018; 198(4):25-32.
  Publicatie openen

• 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial

  Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GA, Hautvast RW, Houwelingen KG van , Stoel MG, Schramm AR, Tjon Joe Gin RM, Man FH de, Hartmann M, Louwerenburg JH, Linssen GCM.
  JACC Cardiovasc Interv. 2018; 11(5):462-469.
  Publicatie openen

• Silent Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.

  Birgelen C von, Kok MM, Sattar N, Zocca P, Doelman C, Kant GD, Löwik MM, Heijden LC van der , Sen H, Linssen GCM.
  JACC Cardiovasc Interv. 2018; 11(5):448-459.
  Publicatie openen

• Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents

  Heijden LC van der , Kok MM, Zocca P, Sen H, Mariani S, Man FH de, Hartmann M, Linssen GCM.
  J Am Heart Assoc. 2018; : pii: e007212. doi: 10.1161/JAHA.117.007212. [epub ahead of print].
  Publicatie openen

• Prediabetes and its Impact on Clinical Outcome After Coronary Intervention in a Broad Patient Population

  Kok MM, Birgelen C von , Sattar N, Zocca P, Löwik MM, Danse PW, Linssen GCM.
  EuroIntervention 2018; :doi: 10.4244/EIJ-D-17-01067. [Epub ahead of print].
  

• Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients

  Birgelen C von, Heijden LC van der, Basalus MW, Kok MM, Sen H, Louwerenburg HW, Houwelingen KG van , Linssen GCM, Palen J van der .
  JAMA Cardiol 2017; 2(3):268-276.
  

• TCT-357 Impact of Gender and Age on 3-Year Clinical Outcome and Chest Pain of Patients With Coronary Artery Disease Treated With Contemporary Drug-Eluting Stents: A Patient-Level Pooled Analysis

  Kok M, Heijden L van der, Lowik M, Zocca P, Doggen CJ, Danse P, Anthonio RL, Hartmann M, Linssen GCM, Maas A, Mehran R, Birgelen C von.
  J Am Coll Cardiol 2016; 68(18S):B146.
  Publicatie openen

• TCT-170 Clinical Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From DUTCH PEERS (TWENTE II) Randomized Trial

  Houwelingen KG van, Heijden L van der, Lam MK, Lowik M, Danse P, Tjon Joe Gin RM, Jessurun GA, Anthonio RL, Sen H, Linssen GCM, IJzerman MJ, Doggen CJ, Birgelen C von.
  J Am Coll Cardiol 2016; 68(18S):B70.
  Publicatie openen

• Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial

  Houwelingen KG van, Heijden LC van der, Lam MK, Kok MM, Löwik MM, Louwerenburg JW, Linssen GCM, IJzerman MJ, Doggen CJ, Birgelen C von.
  Heart Vessels. 2016; 31(11):1731-1739.
  Publicatie openen

• Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

  Birgelen C von, Kok MM, Heijden LC van der, Danse PW, Schotborgh CE, Scholte M, Gin RM, Somi S, Houwelingen KG van, Stoel MG, Man FH de, Louwerenburg JH, Hartmann M, Zocca P, Linssen GCM, Palen J van der, Doggen CJ, Löwik MM.
  Lancet 2016; :[Epub ahead of print].
  Publicatie openen

• Pseudomonas aeruginosa meningitis after visiting a swimming pool a complicated dive: a case report

  Knapen DG, Mulder B, DeSouza F, Linssen GCM, Veneman Th.
  Neth J Crit Care 2016; :.
  Publicatie openen

• Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERS

  Huisman J, Heijden LC van der , Kok MM, Louwerenburg JH, Danse PW, Jessurun GA, Man FH de, Löwik MM, Linssen GCM, Ijzerman MJ, Doggen CJ, Birgelen C von.
  J Cardiol 2016; pii: S0914-5087(16)30142-3:.
  Publicatie openen

• Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial

  Heijden LC van der , Kok MM, Danse PW, Schramm AR, Hartmann M, Löwik MM, Linssen GCM, Stoel MG, Doggen CJ, Birgelen C von.
  Am Heart J 2016; 176:28-35.
  Publicatie openen

• The magnitude and management of chronic heart failure in the netherlands

  Groot S de, Sadacharan S, Linssen GCM.
  Eur J Heart Fail 2016; 18:188, suppl 1.
  

• Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials

  Kok MM, Heijden LC van der, Sen H, Danse PW, Löwik MM, Anthonio RL, Louwerenburg JH, Man FH de, Linssen GCM, IJzerman MJ, Doggen CJ, Maas AH, Mehran R, Birgelen C von.
  JACC Cardiovasc Interv. 2016; 9(6):553-61.
  

• Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial

  Heijden LC van der, Kok MM, Lam MK, Danse PW, Linssen GCM.
  Clin Res Cardiol 2016; 105(3):206-215.
  Publicatie openen

• Urine measurement indicates the plasma brain natriuretic peptide concentration during optimization of heart failure treatment

  Hahn RG, Jaarsma T, Waldréus N, Linssen GCM.
  Scand J Clin Lab Invest 2015; 17:1-6.
  Publicatie openen

• Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers 2-year outcome in patients of the DUTCH PEERS trial

  Heijden LC van der, Kok MM, Lam MK, Danse PW, Schramm AR, Jessurun GA, Tjon Joe Gin RM, Houwelingen KG van, Hautvast RW, Linssen GCM, Sen H, Löwik MM, IJzerman MJ, Doggen CJ, Birgelen C von.
  Clin Res Cardiol 2015; :.
  Publicatie openen

• Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS-Randomized Trial

  Heijden LC van der, Lam MK, Danse PW, Jessurun GA, Tjon Joe Gin RM, Houwelingen KG van, Hautvast RW, Linssen GCM, Sen H, Löwik MM, IJzerman MJ, Doggen CJ, Birgelen C von, Anthonio RL, Louwerenburg JH, Man FH de, Stoel MG, Tandjung K.
  JACC Cardiovasc Interv 2015; 8(7):889-99.
  Publicatie openen

• Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: Insights from 2-year follow-up of the TWENTE trial

  Lam MK, Sen H, Tandjung K, Löwik MM, Basalus MW, Mewes JC, Stoel MG, Houwelingen KG van, Linssen GCM, IJzerman MJ, Doggen CJ, Birgelen C von.
  Catheter Cardiovasc Interv 2015; 85(4):524-31.
  Publicatie openen

• Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

  Löwik MM, Lam MK, Sen H, Tandjung K, Houwelingen KG van, Man FH de, Stoel MG, Louwerenburg JH, Linssen GCM, Doggen CJ, Birgelen C von, .
  EuroIntervention. 2015; 10(11):1276-9.
  Publicatie openen

• Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.

  Sen H, Lam MK, Tandjung K, Löwik MM, Stoel MG, Man FH de, Louwerenburg JH, Houwelingen GK van, Linssen GCM, Doggen CJ, Basalus MW, Birgelen C von.
  Catheter Cardiovasc Interv. 2015; 85 (1):74-81. doi: 10.1002/ccd.25464. Epub 2014 Mar 14. .
  Publicatie openen

• Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study

  Luttik ML, Jaarsma T, Geel PP van, Brons M, Hillege HL, Hoes AW, Jong R de, Linssen GCM, Lok DJ, Berge M, Veldhuisen DJ van.
  Eur J Heart Fail 2014; 16(11):1241-8.
  Publicatie openen

• Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial

  Houwelingen KG van, Sen H, Lam MK, Tandjung K, Löwik MM, Man FH de, Louwerenburg JH, Stoel MG, Hartmann M, Linssen GCM, Doggen CJ, Birgelen C von.
  Catheter Cardiovasc Interv 2014; :.
  Publicatie openen

• Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and non-enrolled TWENTE registry

  Sen H, Lam MK, Tandjung K, Löwik MM, Houwelingen KG van, Stoel MG, Louwerenburg HW, Man FH de, Linssen GCM, Grandjean JG, Doggen CJ, Birgelen C von.
  Int J Cardiol 2014; 176(3):885-90. doi: 10.1016/j.ijcard.2014.08.036 Epub 2014 Aug 13.
  Publicatie openen

• Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications

  Sen H, Lam MK, Tandjung K, Basalus MW, Man FH de, Louwerenburg JH, Stoel MG, Houwelingen GK van, Löwik MM, Linssen GCM, Said SA, Nienhuis MB, Verhorst PM, Palen J van der, Birgelen C von.
  EuroIntervention 2014; 10(6):664-71.
  

• Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial (1)

  Lam MK, Tandjung K, Sen H, Basalus MW, Houwelingen KG van, Stoel MG, Louwerenburg JW, Linssen GCM, Said SA, Nienhuis MB, Man FH de, Palen J van der, Birgelen C von.
  EuroIntervention 2014; (9):1-8.
  

• Safety of second generation drug-eluting stents three years after randomised use in the TWENTE trial

  Löwik MM, Lam MK, Sen H, Tandjung K, Houwelingen KG van, Man FH de, Stoel MG, Louwerenburg JH, Linssen GCM, Doggen CJ, Birgelen C von.
  EuroIntervention 2014; :.
  

• Update Hartfalen en optimaal gebruik van (NT-pro)BNP

  Linssen GCM.
  Analyse 2014; 69:44-49.
  

• Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial

  Lam MK, Tandjung K, Sen H, Basalus MW, Houwelingen KG van, Stoel MG, Louwerenburg JW, Linssen GCM, , Nienhuis MB, Man FH de , Palen J van der, Birgelen J von.
  EuroIntervention 2014; 11 (2):180-7.
  Publicatie openen

• Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: insights from 2-year follow-up of the TWENTE trial

  Lam MK, Sen H, Tandjung K, Löwik MM, Basalus MW, Mewes JC, Stoel MG, Houwelingen KG van, Linssen GCM, IJzerman MJ, Doggen CJ, Birgelen C von.
  Catheter Cardiovasc Interv 2014; :Epub Apr 18.
  Publicatie openen

• Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): Rationale and study design of the randomized TWENTE III multicenter trial

  Lam MK, Sen H, Tandjung K, Houwelingen KG van, Vries AG de, Danse PW, Schotborgh CE, Scholte M, Löwik MM, Linssen GCM, IJzerman MJ, Palen J van der, Doggen CJ, Birgelen C von.
  Am Heart J 2014; 167(4):445-51. doi: 10.1016/j.ahj.2013.11.014.
  Publicatie openen

• Type D, coping and self-care in chronic heart failure patients

  Ree R van der, Schiffer AA, Rodijk E, Weevers M, Linssen GCM.
  J Prec Cardiol 2014; 3:404-411.
  

• Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting xience V stents in the randomized TWENTE trial: Comparison of 2-year clinical outcome

  Sen H, Lam MK, Tandjung K, Löwik MM, Stoel MG, Man FH de, Louwerenburg JH, Houwelingen GK van, Linssen GCM, Doggen CJ, Basalus MW, Birgelen C von.
  Catheter Cardiovasc Interv 2014; :doi: 10.1002/ccd.25464 [Epub ahead of print].
  Publicatie openen

• Highly deliverable third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

  Birgelen C von, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, Houwelingen GK van, Schramm AR, Gin RM, Louwerenburg JW, Man FH de, Stoel MG, Löwik MM, Linssen GCM, Said SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K.
  Lancet 2014; 383(9915):413-23.
  

• Third generation zotarolimus eluting and everolimus eluting stents

  Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, Houwelingen GK van, Schramm AR, Gin RM, Louwerenburg JW, Man FH de, Stoel MG, Löwik MM, Linssen GCM, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K.
  Lancet 2014; 383(9915):413-423.
  Publicatie openen

• Women treated with second generation zotarolimus eluting resolute stents and everolimus eluting xience V stents

  Tandjung K, Basalus MW, Sen H, Stoel MG, Houwelingen KG van, Louwerenburg JH, Man FH de, Linssen GCM, , Kleijne MA, Palen J van der, Birgelen C von.
  Catheter Cardiovasc Interv. 2013; 82(3):396-405.
  Publicatie openen

• Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World patients

  Tandjung K, Sen H, Lam MK, Basalus MW, Louwerenburg JH, Stoel MG, Houwelingen KG van, Man FH de, Linssen GCM, , Nienhuis MB, Löwik MM, Verhorst PM, Palen J van der , Birgelen C von.
  J Am Coll Cardiol. 2013; 61(24):2406-16.
  Publicatie openen

• Type D, coping and self-care in chronic heart failure patients

  Ree R van der, Schiffer AA, Rodijk E, Weevers M, Linssen GCM.
  J Prev Cardiol 2013; 3:404-411.
  Publicatie openen

• Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents

  Sen H, Tandjung K, Basalus MW, Löwik MM, Houwelingen GK van, Stoel MG, Louwerenburg HW, Man FH de, Linssen GCM, Nijhuis RLG, Nienhuis MB, Verhorst PM, Palen J van der, Birgelen C von.
  EuroIntervention 2012; 8(6):664-71.
  

• Ventricular Tachycardia during treatment with Modafinil for narcolepsy: a case report

  Binnenmars H, Idzerda HHD, Tan HL, Linssen GCM.
  Internat J Clin Med 2012; 3:513-517.
  Publicatie openen

• Comparison of frequency of periprocedural myocardial infarction in patients with and without Diabetes Mellitus

  Tandjung K, Houwelingen KG van, Jansen H, Linssen GCM, Nijhuis RLG.
  Am J Cardiol 2012; 110:1561-1567.
  Publicatie openen

• Design and methodology of the COACH-2 (Comparative study on guidelines adherence and patient compliance in heart failure patients) study: HF clinics versus primary care in stable patients on optimal therapy

  Luttik ML, Brons M, Jaarsma T, Hillege HL, Hoes A, Linssen GCM.
  Neth Heart 2012; 20:307-312.
  Publicatie openen

• A randomized controlled trial in second generation zotarolimus-eluting resolute stents versus everolimus-eluting xience V stants in real-world patients: the Twente trial

  Birgelen C von , Basalus MW, Tandjung K, Linssen GCM, .
   J Am Coll Cardiol 2012; 59:1350-1361.
  Publicatie openen